Lonza

1. Executive Summary (Confidence: High)

In 2024, Lonza initiated a pivotal "One Lonza" strategy aimed at refocusing the organization on its core CDMO business and strengthening its foundation for long-term value creation. Led by new CEO Wolfgang Wienand and Chair Jean-Marc Huët, the company reported annual sales of CHF 6. billion and a robust CORE EBITDA margin of 29.0%. A cornerstone of its 2024 performance was the strategic acquisition of Genentech’s large-scale biologics manufacturing site in Vacaville, US, from Roche for USD 1. billion, significantly expanding its mammalian manufacturing network. Furthermore, Lonza announced its intent to exit the Capsules & Health Ingredients (CHI) business to prioritize high-growth "Specialized Modalities" and "Advanced Synthesis" platforms.